Search clinical trials for: Genetically modified T cells # 1138

Total 1728 results

University of Cologne

Unknown

Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides (TECLA)

CD30 Positive Cutaneous T Cell Lymphoma | CD30 Positive Transformed Mycosis Fungoides

Germany
Chinese PLA General Hospital

Unknown

Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 (CART-138)

Multiple Myeloma

China
Adaptimmune

Completed

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

Carcinoma | Non-Small Cell Lung Cancer

United States, Spain, United Kingdom, Canada
Adaptimmune

Active, not recruiting

AFPᶜ³³²T in Advanced HCC

Hepatocellular Cancer | AFP Expressing Tumors

United States, United Kingdom, France, Spain
In8bio Inc.

Recruiting

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Glioblastoma

United States
Adaptimmune

Terminated

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Melanoma

United States
Adaptimmune

Completed

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Melanoma | Head and Neck Cancer | Urothelial Carcinoma | Bladder Urothelial Carcinoma

United States, Canada, Spain
Adaptimmune

Active, not recruiting

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Melanoma | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Urinary Bladder Cancer | Synovial Sarcoma | Gastroesophageal Junction | Myxoid Round Cell Liposarcoma

United States, Canada
GlaxoSmithKline

Completed

Redirected Auto T Cells for Advanced Myeloma

Multiple Myeloma

United States
Tessa Therapeutics

Active, not recruiting

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (CERTAIN)

Anaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

United States
Nanfang Hospital of Southern Medical University
Guangdong Yike Gene Science and Technology CO.,Ltd

Unknown

Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified

Beta Thalassemia Major

China
University of Pennsylvania

Completed

Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy (MazF)

HIV

United States
Adaptimmune

Terminated

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

Solid and Hematological Malignancies

United States, Canada
Affiliated Hospital to Academy of Military Medical...

Unknown

Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT

Acute Leukemia

China
Affiliated Hospital to Academy of Military Medical...

Unknown

Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases

Non-Small-Cell Lung Cancer With Bone Metastases

China
Memorial Sloan Kettering Cancer Center
Stanford University; Juno Therapeutics, Inc.

Active, not recruiting

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Solid Tumors

United States
Sorrento Therapeutics, Inc.

Withdrawn

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic Antigen

United States
Roger Williams Medical Center

Suspended

Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas

Metastatic Cancers

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

CAR | Malignant Tumors

China
Adaptimmune
ICON plc

Terminated

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Esophageal Cancer | Esophagogastric Junction Cancer

United States, Canada, Spain
Roger Williams Medical Center

Terminated

Trial of Second Generation Designer T Cells in Colorectal Carcinoma

Colorectal Cancer

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) (NATELLA)

Nasopharyngeal Carcinoma

United States
Charite University, Berlin, Germany

Unknown

Metabolic Changes Induced by Genetically Modified Potatoes

Glucose Metabolism | Satiety | Endocrine Metabolism

Germany
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Brain Tumor | Liver Cancer | Ovarian Tumor | Acute Myeloid and Lymphoid Leukemias

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Pancreatic Cancer | Malignant Mesothelioma | Triple Negative Breast Cancer | Endometrial Cancer | Ovarian Tumor | Other Mesothelin Positive Tumors

China
University College, London

Completed

CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation (CARD)

CD19+ Malignancies: Relapse Post-allogeneic Transplant

United Kingdom
Chinese PLA General Hospital

Unknown

CART-19 Immunotherapy in Mantle Cell Lymphoma

Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Non-hodgkin Lymphoma,B Cell

China
Charite University, Berlin, Germany

Unknown

Long Time Metabolic Changes Induced by Genetically Modified Potatoes

Glucose Metabolism | Satiety | Hormonal Changes

Germany
VIRxSYS Corporation

Active, not recruiting

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

HIV Infection

United States
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Liqun Zou

Recruiting

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Leukemia

China
Adaptimmune
GOG Foundation

Recruiting

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Ovarian Cancer

United States, Spain, France, Canada, United Kingdom
University College, London

Recruiting

Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer (TACTICAL)

Adenocarcinoma of Lung

United Kingdom
Tianjin Medical University Cancer Institute and...

Unknown

Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors

Malignant Solid Tumors

China
IRCCS San Raffaele
Orchard Therapeutics; Fondazione Telethon

Unknown

Gene Therapy for Transfusion Dependent Beta-thalassemia (TIGET-BTHAL)

Beta-Thalassemia

Italy
Southwest Hospital, China

Recruiting

A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Lymphoma | Leukemia

China
University of Pennsylvania

Terminated

Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)

Breast Cancer | Malignant Melanoma

United States
University of Pennsylvania
Adaptimmune

Completed

Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy

HIV Infections

United States
Celgene

Recruiting

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Neoplasms

United States, Belgium, Spain, Switzerland, Canada, France, Germany, Japan, Finland, United Kingdom, Austria, Italy, Netherlands, Norway, Sweden
Sun Yat-sen University
Guangzhou Bio-gene Technology Co., Ltd.

Unknown

Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Children's Mercy Hospital Kansas City
Center for Cell and Gene Therapy, Baylor College of Medicine

Completed

Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma (STALLONe)

Neuroblastoma

United States
Innovative Cellular Therapeutics Co., Ltd.

Unknown

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

Lymphoma, B-Cell | Leukemia, B-Cell

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC

Non Small Cell Lung Cancer

China
Daniel Landi

Terminated

EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma (ExCeL)

Glioblastoma | Gliosarcoma

United States
Castle Creek Biosciences, LLC.

Terminated

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa Dystrophica, Recessive

United States
Changhai Hospital

Recruiting

A Study of IMC008 for Advanced Solid Tumors

Advanced Solid Tumor

China

Search clinical trials for: Genetically modified T cells # 1138

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations